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Case report
Myasthenia gravis without chronic GVHD after allogeneic bone
marrow transplantation
F Baron1, B Sadzot2, F Wang3 and Y Beguin1
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Lie`ge, Belgium
Summary:
A 20-year-old man with aplastic anemia developed
myasthenia gravis (MG) 7 months after bone marrow
transplantation (BMT) from an HLA one locus-
mismatched sister. Proximal muscle weakness
(predominant in the lower limbs) and dysphagia
occurred without any other sign of graft-versus-host
disease (GVHD), 1 month after cessation of immuno-
suppression with cyclosporine. The diagnosis of MG was
based on clinical symptoms and on neurophysiologic
investigations showing a significant increase of the Jitter
in single-fiber electromyography and a significant dec-
remental response during repetitive stimulation at slow
rates, but antibodies against the acetylcholine receptor
(AchRab) were negative. All clinical and neurophysio-
logical signs normalized within 1 month of treatment
with low-dose prednisolone and pyridostigmine, and the
patient is perfectly well 1 year after cessation of all ther-
apy. All cases of BMT-associated MG previously pub-
lished are reviewed in comparison with ours. The orig-
inality of this new observation is that this case is the
only one not associated with chronic GVHD and nega-
tive for AchRab. Alternatively, MG may have been the
sole manifestation of chronic GVHD in this patient.
Keywords: myasthenia gravis; bone marrow transplan-
tation; aplastic anemia
The first case of myasthenia gravis (MG) following bone
marrow transplantation (BMT) was described in 1983.1
Since then, 14 cases of BMT-associated MG have been
reported (Table 1).2–12 In all these cases other signs of
chronic graft-versus-host disease (GVHD) developed dur-
ing the post-transplant period and antibodies to the acetyl-
choline receptor (AchRab) were always positive when
tested. We report a new case of BMT-associated MG which
developed shortly after cessation of immunosuppressive
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therapy without any other sign of GVHD and without Ach-
Rab.
Case report
A 20-year-old man was diagnosed in December 1993 with
severe aplastic anemia (SAA). After failure of treatment by
steroids and vitamin supplements (B6, B12, folic acid), the
patient was referred to us for a BMT procedure from an
HLA one locus-mismatched sister who had had two preg-
nancies but no transfusions. The recipient’s HLA typing
was A10(26), A11; B8, B12(45); Cw6, Cw7; DR3, DR8;
and the donor’s was A10(26), A1; B8, B12(45); Cw6, Cw7;
DR3, DR8. High-resolution class II molecular typing was:
DPB 0401, 0101 in recipient, and 0401, 0301 in donor;
DQB 0201, 0402 in both; DRB1 0301, 0801 in both. The
mother was fully identical with the donor and the father’s
HLA typing was: A1, A11; B8; Cw7; DR3; DPB 0301,
0101; DQB 0201; DRB 0301. After conditioning with
cyclophosphamide (200 mg/kg) and ATG (30 mg/kg),
the patient received an unmanipulated marrow. GVHD
prophylaxis was carried out with ‘short’ methotrexate and
cyclosporine.
The immediate post-transplant course was uneventful
and the patient was discharged on day 27 taking daily
cyclosporine. He regularly attended the outpatient clinic
and did not experience significant complications. He never
developed any sign of acute or chronic GVHD. Routine
skin and mucosa biopsies, as well as Shirmer tests at day
100 and day 180, were negative. After tapering, cyclospor-
ine was discontinued on day 180. Cytogenetic analyses of
bone marrow cells at days 100, 180 and 365 showed a nor-
mal female karyotype (46,XX). FISH analysis of more than
1500 nuclei with probes for the X and Y chromosomes
failed to detect any Y chromosomes. The patient was in
excellent physical shape and had resumed intensive training
in several sports.
Around day 210, he developed abnormal fatigue and
proximal muscle weakness predominant in the lower limbs.
He had serious difficulties in going up stairs, rising from
a chair or from bed and in swallowing. General physical
examination was normal. Upon neurological examination,
we noticed diffuse moderate muscle atrophy of the legs.
The deep tendon reflexes were all brisk and symmetrical
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and the plantar responses were flexor. Sensation to light
touch, pinprick and vibration, as well as examination of
cranial nerves, were normal. Electrophysiological testing
showed normal nerve conduction but a significant dec-
remental response during repetitive stimulation at a rate of
3 per second (14% in the anconeus muscle). Single fiber
electromyography resulted in an increased Jitter value in
the extensor digitorum communis muscle. A diagnosis of
MG was established despite negativity of the AchR anti-
body. Hematological parameters were normal. Antithyro-
globulin antibodies were positive at a titer of 1/76, while
antinuclear, antismooth muscle, antimitochondrial and anti-
microsomial antibodies were negative. Both chest X-ray
films and CT scan were normal. There were no signs of
chronic GVHD. The patient was started on 24 mg/day
prednisolone and 3 · 60 mg/day pyridostigmine. This ther-
apy produced prompt resolution of his symptoms and elec-
trophysiological testing performed 2 months later was nor-
mal. Treatment was stopped by the patient after 2 months
as he felt totally normal. He has remained in clinical and
electrophysiological remission for more than 1 year, and
has not developed any degree of chronic GVHD.
Discussion
The complaints and clinical presentation of this patient are
compatible with a Lambert–Eaton syndrome but certainly
not specific for it. Furthermore, there was no recovery of
power after a series of several voluntary contractions. Elec-
trophysiology was incompatible with that diagnosis. Com-
pound motor unit action potentials did not have a low
amplitude after a single stimulus. At fast rates of stimu-
lation, there was no increase in the amplitude of action
potentials. Single fiber electromyography did not show
Jitter increase when reducing the frequency of stimulation,
a characteristic of Lambert–Eaton syndrome. We therefore
believe that a Lambert–Eaton syndrome was excluded.
The incidence of MG is increased at least 20 times after
BMT compared to that seen in the general population.4 We
described here the 15th such case.1–12 However, this figure
is most probably an underestimate since fatigue is a com-
mon manifestation of chronic GVHD and treatment of
chronic GVHD should be effective in suppressing symp-
toms of MG in mild cases.4 It is not known which BMT
patients are at risk of MG.3,6,8,10 Idiopathic MG is age- and
sex-related, with one peak incidence affecting mostly
women in the second and third decades and another mostly
men in the sixth and seventh decades.13 An HLA haplotype
with B8/DR3 has been associated with early-onset MG,
B7/DR2 and late-onset MG and B35/DR1 with penicillam-
ine-induced MG. Surprisingly, in most BMT cases, patients
were young (6–37 years) males (11 of 14 cases), the donors
were of the opposite sex (eight of 11 cases), and the under-
lying disease was aplastic anemia (seven of 15 cases). HLA
data reported in nine cases showed no association with
these or other haplotypes. This may indicate that the patho-
physiology of BMT-associated MG differs from other
forms of MG. In six cases including ours, MG developed
after discontinuation or tapering of long-term immuno-
suppression and in all cases before ours, MG was associated
with AchRab and chronic GVHD. However, the finding of
AchRab after twin or autologous BMT may constitute evi-
dence against an important role of GVHD in this auto-
immune complication.14 Moreover, a negative association
(not statistically significant) was found between the pres-
ence of AchRab and chronic GVHD.4
The diagnosis of MG is based on a typical clinical pic-
ture, a characteristic electromyographic pattern, a positive
response to cholinesterase inhibitors, and the presence of
AchRab.13 A clinical classification has been proposed,
based on the distribution and severity of symptoms: group
1, ocular; group 2A, mild generalized; group 2B, moder-
ately severe generalized; group 3, acute fulminating; group
4, late severe. Among the 12 evaluable post-BMT cases,
one patient was in group 1, six (including ours) in group
2A, three in group 2B and two in group 3. Contrary to
typical MG, BMT-associated MG has not been associated
with thymic abnormalities and the study of other auto-anti-
bodies failed to uncover consistent findings. A drop in
amplitude of the evoked muscle action potential in repeti-
tive nerve stimulation at a rate of 2 or 3 per second
(decrement >10% between the first response and the small-
est of the next four responses) and an increased Jitter value
in single-fiber EMG are the two typical EMG findings. MG
is an autoimmune disease in which antibodies against the
acetylcholine receptor can be detected. However, about 10–
20% of MG patients do not have detectable AchRab,
including patients with generalized weakness whose disease
corresponds to conventional MG with respect to other clini-
cal, diagnostic, and therapeutic features.13 These patients
probably have antibodies directed at epitopes not present
in the soluble AchR extract.13 Our patient must be included
in this group contrary to all other cases of BMT-associated
MG. Furthermore, the presence of AchRab without MG has
been demonstrated in many BMT recipients,4,14 possibly a
manifestation of subclinical host–recipient interactions.
However, such antibodies have even been detected in
patients with various hematologic disorders not under-
going BMT.15
Therapy of MG following BMT is based on pyridostig-
mine and on treatment of the GVHD process by predniso-
lone, azathioprine and/or cyclosporine. The prognosis is
generally good (MG resolved in eight of 10 patients and
improved in one) but three patients required plasmapheresis
for life-threatening problems, two relapsed and one was still
requiring pyridostigmine, prednisone and cyclosporine 8
years later. Our patient received treatment with low-dose
prednisolone and pyridostigmine for only 2 months, with
complete resolution of all clinical and EMG signs. MG
must therefore be suspected when BMT recipients com-
plain of neuromuscular symptoms even in the absence of
signs of chronic GVHD.
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